Clinical Trial Detail

NCT ID NCT04428151
Title Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

oral cavity cancer

laryngeal squamous cell carcinoma

oropharynx cancer

head and neck squamous cell carcinoma

hypopharynx cancer

Therapies

Lenvatinib + Pembrolizumab

Docetaxel

Paclitaxel

Capecitabine

Cetuximab

Lenvatinib

Age Groups: adult senior

No variant requirements are available.